CriticalFirst-generation antipsychotic, aliphatic-side-chain phenothiazine×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
Pimozide prolongs the QT interval on the electrocardiogram, so an additive effect on QT can be expected with other QT-prolonging drugs such as phenothiazines. The US pimozide label names chlorpromazine among them (pimozide label, US Food and Drug Administration, FDA). Phenothiazine neuroleptics, including chlorpromazine, can increase QT prolongation and the risk of serious ventricular arrhythmias of the torsade de pointes type (chlorpromazine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A4 and CYP2D6 are the main enzymes that metabolise pimozide, and inhibition of CYP2D6 may raise pimozide levels and the risk of QT prolongation (pimozide SmPC, AEMPS). The Spanish chlorpromazine SmPC describes phenothiazines such as chlorpromazine as strong CYP2D6 inhibitors (chlorpromazine SmPC, AEMPS). The documents do not say how much chlorpromazine raises pimozide levels. With paroxetine, another strong CYP2D6 inhibitor, the pimozide area under the curve rose by 151% (pimozide FDA label).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. With chlorpromazine, QT prolongation that can trigger a ventricular arrhythmia is common. Ventricular tachycardia, ventricular fibrillation, torsade de pointes, cardiac arrest and sudden death have been reported with unknown frequency (chlorpromazine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With pimozide, very rare cases of QT prolongation, ventricular arrhythmias and torsade de pointes have been reported, even in people without risk factors. Ventricular tachycardia and ventricular fibrillation, sometimes fatal, have also been reported (pimozide SmPC, AEMPS). QT prolongation is worse with a slow heart rate, low potassium and congenital or acquired QT prolongation (chlorpromazine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish pimozide summary of product characteristics (SmPC) contraindicates pimozide with drugs known to prolong the QT interval and names other antipsychotics among them, including phenothiazines such as chlorpromazine. It also contraindicates drugs that inhibit the enzyme CYP2D6 (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US pimozide label states that pimozide should not be given with chlorpromazine and contraindicates pimozide with strong CYP2D6 inhibitors (pimozide label, US Food and Drug Administration, FDA). According to its Spanish SmPC, chlorpromazine is a strong CYP2D6 inhibitor (chlorpromazine SmPC, AEMPS). The Spanish chlorpromazine SmPC, in turn, does not recommend chlorpromazine with other QT-prolonging drugs, including other antipsychotics (chlorpromazine SmPC, AEMPS). No document states how long to wait after stopping pimozide before starting chlorpromazine. The mean elimination half-life of pimozide in people with schizophrenia is about 55 hours, and that of chlorpromazine about 30 hours (pimozide and chlorpromazine SmPCs, AEMPS). Before starting a neuroleptic, where the clinical situation allows, rule out a heart rate below 55 beats per minute, low potassium and congenital QT prolongation. Except in emergencies, include an electrocardiogram (ECG) in the initial assessment (chlorpromazine SmPC, AEMPS). Pimozide is contraindicated in known low potassium or magnesium and clinically significant bradycardia. Record an ECG before starting pimozide and periodically during treatment, and stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Clorpromazina (nº registro 42934), sección 4.4 (2023)– AEMPS, CIMA, nº registro 42934 (Largactil 100 mg comprimidos recubiertos con película, Neuraxpharm Spain), revisión 07/2023, secciones 4.3, 4.4, 4.5, 4.8 y 5.2